原始来源记录
本季度更新重申,用于阻塞性睡眠呼吸暂停的aroxybutynin/atomoxetine(AD109,拟定名称Oxnimbi)的NDA正处于FDA审查中,PDUFA目标日期为2027年2月28日。公司继续推进潜在上市前的商业化准备活动。
EX-99.1 2 apmd-ex99_1.htm EX-99.1 EX-99.1 EX-99.1 Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update • New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and atomoxetine) tablets, for oral use, remains under U.S. Food and Drug Administration (“FDA”) review with a February 28, 2027, Prescription Drug User Fee Act (“PDUFA”) goal date • Commercial readiness activities advance in preparation for a potential U.S. launch • Presented five abstracts at CHEST 2026, including two late-breakers, highlighting AD109 Phase 3 clinical data and the burden of OSA • $351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter